pharma · Carcinoma, Non-Small-Cell Lung
Centus Biotherapeutics Europe Limited
Barinthus Biotherapeutics drug portfolio — 1 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Portfolio lens on 1 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Barinthus Biotherapeutics drug portfolio — 1 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
US regulatory status: approved. Molecular target: Vascular endothelial growth factor A, long form.